03.08.2012 • NewsLundbeckgenericspharmaceutical industry

Lundbeck in Deal with Teva over Copycat Antidepressant

Danish pharmaceutical group Lundbeck has agreed a deal with Israel's Teva over a copycat version of the Danish company's antidepressant drug Cipralex, it said on Thursday.

While a court injunction against copying Cipralex still stands, the parties have agreed a deal which will put an end to further court action, a Lundbeck spokesman said, while declining to give further details.

"I can confirm that we have reached a settlement but it is not a money settlement," the spokesman said.

Ratiopharm, owned by Teva, had produced copies of Cipralex while the drug was still patent protected.

Last week, EU antitrust regulators charged nine drug companies including Germany's Merck and Lundbeck with blocking the entry of a cheaper generic medicine to market.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.